Tellus BioVentures is a biotechnology investment fund focused on early-stage innovation and company formation.

About Us

Tellus BioVentures is a biotechnology investment fund focused on early-stage innovation and company formation.

About Us

Featured News

FDA Grants Fast Track Status to Aegle Therapeutics’ AGLE-102 for the Treatment of Dystrophic Epidermolysis Bullosa

10/01/20 The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AGLE-102™ for the treatment of patients with DEB. Evangelos Badiavas, MD, PhD, Chief Scientific Officer at Aegle Therapeutics said, “This designation will expedite the development and regulatory review of AGLE-102 and highlights the importance…

Continue reading

Aegle Therapeutics Completes $6.5M Series A Financing

9/29/20 Aegle Therapeutics Corporation, a first-in-class biotechnology company developing extracellular vesicles as therapy, today announced the completion of a $6.5M Series A round of financing.
Aegle is also pleased to announce the appointment of Heidi Kempinski as Senior Vice President, Head of Operations…

Continue reading

Mission

  • To uncover and accelerate promising life science innovation
  • To enable talented entrepreneurs and innovators
  • To serve patients with unmet needs
Learn More

Investments

We make select early investments at the Seed stage in private biotech ventures as the lead or sole investor and participate in Series-A investments.

Company Formation

We launch and fund de novo companies to advance important innovations that may otherwise lack the proper resources to progress efficiently.

Approach & portfolio